Vistagen Therapeutics is doubling down on its lead social anxiety candidate, even after the asset failed a phase 3 trial last December. | Vistagen Therapeutics is doubling down on its lead social ...

BridgeBio Pharma has taken another step toward the potential approval of its muscle weakness drug candidate BBP-418, ...

“Strategic transformations are a common and often successful approach in biotechnology,” Rami Levin, who took over as CEO of ...

BD has inked a technological partnership with automation provider Sinteco, aimed at pharmacy robotics. | The goal is to ...

A new method for safely inserting large chunks of DNA into genomes has now measured up in mice, potentially paving the way ...

Funding from the National Institutes of Health (NIH) generated $94.15 billion in economic activity and supported 390,863 jobs in 2025, according to a ...

Salspera has set out plans for a $91 million IPO to fund the phase 3 study of its bacteria-based cancer therapy. | Salspera has set out plans for a $91 million IPO to fund the phase 3 study of its ...

This is a developing story. Please check back for updates. | After a tumultuous tenure marked by recent clashes with the ...

Bay Area laboratory solutions company Agilent Technologies has agreed to acquire Biocare Medical, a pathology solutions business, in an all-cash transaction valued at $950 million. | Bay Area ...

In a strikingly blunt briefing, a senior FDA official accused uniQure of pushing “distorted” data to mask a “failed” therapy ...

Monoclonal antibodies have become one of the most established and clinically successful therapeutic modalities, supported by ...

Voyager Therapeutics has hit pause on a preclinical Alzheimer’s disease program just eight months after unveiling the asset. The neurology biotech announced back in July 2025 that it was adding a new ...